VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Medilink Therapeutics Announces B7-H3 ADC Achieves Primary Endpoint in Nasopharyngeal Carcinoma Phase III Study
Medilink Therapeutics Announces B7-H3 ADC Achieves Primary Endpoint in Nasopharyngeal Carcinoma Phase III Study
May 23, 2026 19:00 CST Updated 19:10
Share: